Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Malignancies clinical trials
Every US clinical trial registered for Advanced Malignancies — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
11 US clinical trials · 2 currently recruiting
The research picture
Advanced Malignancies has 11 registered US clinical trials, 2 of them open to new participants right now — about 18% of the total.
- 2
- recruiting participants now
- 18%
- of trials open to enrollment
- 2
- in Phase 3–4 (later-stage)
- 2
- top sponsor: Novartis Pharmaceuticals
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
BioInvent International AB
NCT04752826
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis Pharmaceuticals
NCT06401356
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
NCT05059522
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
NCT02383212
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
MedImmune
NCT02013804
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Astellas Pharma
NCT01284192
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Astellas Pharma Global Development
NCT04837196
Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State
Mirati Therapeutics
NCT01930006
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Novartis Pharmaceuticals
NCT00421044
Maintenance Study on the Long Term Safety of XL999
Symphony Evolution
NCT00955084
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 3 | 2 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Advanced Malignancies Trial Landscape
ClinicalTrials.gov lists 11 US studies indexed under Advanced Malignancies, and 2 of those are currently open to recruitment — roughly 18% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Advanced Malignancies shows 2 late-stage studies (Phase 3 and Phase 4 combined) alongside 9 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Advanced Malignancies is led by Novartis Pharmaceuticals with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 11 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Advanced Malignancies?
PlainTrial tracks 11 US clinical trials for Advanced Malignancies, of which 2 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Advanced Malignancies?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.